Despite likely new MS drugs, US neurologists continue to see significant near ... The Pharma Letter In fact, interest in BG-12, along with Biogen Idec's PEG-Avonex, Abbott/Biogen Idec's daclizumab and Roche/Genentech's ocrelizumab, has increased significantly compared to a year ago. While the greatest percentage of surveyed neurologists believe that ... |
